Tilray Brands Announces Issuance of Series A Preferred Stock

3 years ago

Goal is to Enhance Corporate Governance with Proposed Charter AmendmentNEW YORK and LEAMINGTON, Ontario, Feb. 22, 2023 (GLOBE NEWSWIRE) --…

Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET

3 years ago

WARREN, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company…

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

3 years ago

CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a preclinical-stage biotechnology company committed to…

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

3 years ago

BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical…

SmileDirectClub Adds Innovative Sensitivity-Free Whitening Kit to Its Oral Care Portfolio

3 years ago

SmileDirectClub Sensitivity-Free Whitening Kit SmileDirectClub Sensitivity-Free Whitening Kit Latest advancement in teeth whitening provides gentle option for customerswith tooth sensitivityNASHVILLE,…

Oncocyte Completes Razor Genomics Transaction

3 years ago

Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product…

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

3 years ago

BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of…

ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology

3 years ago

Monday, February 27th at 10am ETMADRID, Spain and BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code:…

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

3 years ago

The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds…

Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®

3 years ago

Switzerland is latest market for Alimera in continued geographic expansionATLANTA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:…